Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

INTRODUCTION: Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can reduce risk of cardiovascular disease (CVD) in persons living with type 2 diabetes, however the mechanisms explaining this cardiovascular benefit are still debated. We investigated changes in the plasma lipidome f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zobel, Emilie H, Wretlind, Asger, Ripa, Rasmus S, Rotbain Curovic, Viktor, von Scholten, Bernt J, Suvitaival, Tommi, Hansen, Tine W, Kjær, Andreas, Legido-Quigley, Cristina, Rossing, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451300/
https://www.ncbi.nlm.nih.gov/pubmed/34518158
http://dx.doi.org/10.1136/bmjdrc-2021-002395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451300/
https://www.ncbi.nlm.nih.gov/pubmed/34518158
http://dx.doi.org/10.1136/bmjdrc-2021-002395

Ejemplares similares